Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Yarrow Bioscience's interest expense for the
three
months ended in Jun. 2026 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Yarrow Bioscience's Operating Income for the
three
months ended in Jun. 2026 was $ -3.10 Mil. Yarrow Bioscience's Interest Expense for the
three
months ended in Jun. 2026 was $ 0.00 Mil.
Yarrow Bioscience has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Yarrow Bioscience's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as
Yarrow Bioscience had no long-term debt (1).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Yarrow Bioscience Inc has no debt.
Yarrow Bioscience Interest Expense Historical Data
* Premium members only.
The historical data trend for Yarrow Bioscience's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yarrow Bioscience (YARW) has a Interest Expense of $0.00 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Yarrow Bioscience and its competitors.
Is Yarrow Bioscience's Interest Expense too high?
Yarrow Bioscience's current Interest Expense is $0.00 Mil. Overall, Yarrow Bioscience has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Yarrow Bioscience's Interest Expense compare to CGTX and RANI?
Yarrow Bioscience's Interest Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Yarrow Bioscience and its competitors. Yarrow Bioscience's current Interest Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yarrow Bioscience stock overvalued right now?
Yarrow Bioscience (YARW) has a current Interest Expense of $0.00 Mil. The current Interest Expense is $0.00 Mil. Yarrow Bioscience's overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Yarrow Bioscience (YARW), the current Interest Expense is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
13GF Score
Get the complete analysis for YARW
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YARW has been successfully added to your 
